SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing intense volatility as traders react to contradictory signals regarding the Iran conflict, with markets weighing optimistic peace deal rumors against reports of continued military escalation and supply chain disruptions. The community remains deeply divided, with many actively debating whether the current price action represents a speculative bubble prone to a sharp correction or a sustained rally driven by real-world constraints on the Strait of Hormuz.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is facing significant downward pressure as investors react to escalating geopolitical tensions in the Middle East and a sharp spike in oil prices, fueling fears of inflation and economic instability. Community sentiment remains highly divided and volatile, with market participants debating whether the current selloff is a necessary market correction or a result of artificial manipulation following conflicting leadership signals regarding the conflict.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market sentiment as investors weigh volatile geopolitical headlines against high-stakes Q1 delivery expectations. Community discourse is sharply divided between bulls banking on a delivery beat and AI-driven growth, and bears highlighting potential margin compression, regulatory headwinds, and the broader risks of a tech-heavy portfolio in a cooling demand environment.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community actively debate the economic and geopolitical implications of the former President's latest address regarding the Iran conflict. The discussion is heavily polarized, with critics pointing to market volatility and concerns over rhetoric, while supporters remain focused on political alignment and ongoing market strategies.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following the announcement of a new contract from a NATO ally for its Black Widow drones, sparking intense debate among community members regarding the company's long-term contract visibility versus ongoing volatility and dilution concerns. Investors are actively discussing the stock's role in the broader defense sector, with many focused on how recent strategic partnerships and government procurement trends might impact future growth.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently experiencing significant price volatility, driven by a combination of broader market anxiety regarding the geopolitical situation in Iran and high-frequency trading activity around the upcoming SpaceX IPO narrative. The community remains deeply polarized, with bulls pointing to the proximity of the BlueBird launch and strategic institutional partnerships as catalysts for a potential reversal, while bears are focusing on technical breakdowns, production delays, and negative price momentum to justify their short positions.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is experiencing intense volatility as traders react to President Trump's recent address, which signaled an escalation in military operations against Iran rather than the ceasefire market participants had hoped for. The community is sharply divided, with bulls trapped in 'fake-out' rallies while bears argue that persistent geopolitical uncertainty and the potential for a prolonged ground conflict will keep energy prices elevated and pressure tech valuations.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as traders debate the sustainability of the semiconductor sector's prolonged rally amidst ongoing geopolitical tensions and high oil prices. While some community members are betting on a major correction, arguing that AI-driven valuation expansion is reaching a breaking point, others warn against shorting an essential industry during a cycle where hardware demand remains a critical component of national security.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense market volatility and increased volume as speculation mounts over a potential acquisition by tech giants like Amazon or SpaceX, with the community actively debating whether current buyout rumors are substantiated or merely a play for leverage. Traders are closely tracking the intersection of GSAT's critical satellite spectrum assets, the long-standing Apple partnership, and the broader space industry land-grab for direct-to-device connectivity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares (SOXL) is experiencing extreme volatility driven by shifting geopolitical headlines surrounding the ongoing conflict in the Middle East and concerns over semiconductor supply chains. The community remains deeply divided, with some traders actively scaling into long positions to capitalize on oversold conditions, while skeptics warn of potential bull traps and argue that the broader structural trend remains bearish.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Reviva to use the proceeds for its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia.</li><li>The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026.</li><li>Reviva implemented a 1-for-20 reverse share split on March 9.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plummeted more than 40% in pre-market trading on Thursday, after the company priced its public offering to raise about $10 million.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/RVPH">RVPH shares</a> would fall to a record low.<h2 class="st-heading-2">Offering At 20% Discount</h2>The offering consists of 6.67 million shares, as well as Series G and Series H warrants to purchase an equal number of shares, all priced at a combined $1.50 per share, for total gross proceeds of about $10 million. This represents a 20% discount on the stock’s closing price of $1.87 on Wednesday.Both warrants are immediately exercisable: Series G is valid for 5 years, and Series H expires in 12 months, the pharmaceutical company said. The offering is expected to close around March 20, 2026.Reviva said it plans to use the proceeds, along with existing cash, to support research and development, including its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia. Funds will also be used for working capital and general corporate needs.<h2 class="st-heading-2">Reviva To Begin A Second Phase 3 Trial In First Half Of 2026</h2>In January, the U.S. Food and Drug Administration (FDA) recommended conducting a second Phase 3 trial for its schizophrenia drug candidate to get additional efficacy and safety data before submitting a New Drug Application (NDA).The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026, subject to funding. Reviva said existing data showed strong efficacy across key symptoms of schizophrenia and a favorable safety profile, with over 900 patients treated so far.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market slump, retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier.Chatter was mixed. One user said the stock’s upside looks “amazing” and the company may require $60 to $70 million to complete the study.<stembedurl>https://stocktwits.com/Blaze321/message/647942525</stembedurl>Another user said there was “no chance” of raising the required funds.<stembedurl>https://stocktwits.com/Gropius/message/647911923</stembedurl>Reviva had announced a 1-for-20 reverse share split earlier this month, with the stock trading on an ex-split basis from March 9.For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Why Did RVPH Stock Crash 40% In Pre-Market Today?

Reviva Pharmaceuticals Holdings company priced its $10 million offering at a 20% discount from Wednesday’s close.

Equity

The company priced its $10 million offering at a 20% discount from Wednesday’s close.

Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...

<ul class="summary-bullets"><li>FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and expand brilaroxazine’s safety database.</li><li>The company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026.</li><li>The company’s current estimates project that the trial cost will be around $60 million.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plunged more than 50% on Tuesday after the FDA called for an additional Phase 3 trial of the company’s schizophrenia treatment drug, dealing a significant setback to its regulatory timeline.In written feedback, the FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and further expand brilaroxazine’s safety database before submitting a new drug application (NDA).Subject to sufficient financing, the company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026. The study is expected to mirror the design of the completed RECOVER Phase 3 trial. The FDA also provided guidance on data analysis and presentation, as well as requirements for animal pharmacokinetics, human abuse potential, and renal and hepatic impairment studies.<h2 class="st-heading-2">Cost Of The Trial</h2>According to an SEC filing, the company’s current estimates project the trial cost at around $60 million, consisting of roughly $35 million in direct trial costs and approximately $24 million in general and administrative expenses.The FDA’s recommendation follows its review of two completed randomized, double-blind, placebo-controlled studies, including one Phase 2 and one Phase 3 trial with a one-year open-label extension. Across these studies, brilaroxazine demonstrated efficacy across major schizophrenia symptom domains, including negative symptoms, in 790 participants, Reviva added.At a meeting on December 18, Reviva shareholders approved the reverse stock split charter amendment, allowing the board to implement a 1-for-2 to 1-for-20 split at its discretion before Dec. 31, 2026. Companies generally use a reverse split to meet the $1.00 minimum bid price requirement under Nasdaq listing compliance.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/RVPH">RVPH</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img style="aspect-ratio:919/97;" src="https://news.stocktwits-cdn.com/RVPH_png_6f1a479b84.webp" alt="RVPH.png" width="919" height="97"><figcaption>RVPH's Sentiment Meter and Message Volumes at 10:15 a.m. ET on Dec. 23, 2025 | Source: Stocktwits</figcaption></figure>One user opined on how the company could raise funds to cover the trial costs.<stembedurl>https://stocktwits.com/jgo1/message/639964998</stembedurl>Another user speculated about the trial timelines.<stembedurl>https://stocktwits.com/hawkeye45691/message/639962383</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spot-silver-crosses-70-an-ounce-for-the-first-time/cLep81RREuz">Spot Silver Crosses $70 An Ounce For The First Time</a> For updates and corrections, email newsroom[at]stocktwits[dot]com

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did RVPH Stock Crash 50% Today?

The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.

Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...

Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...

Brokers Offer Predictions for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Reviva Pharmaceuticals Holdings Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.08	--	--	N/A
Q4 '25	-$1.13	$0.72	163.91%	BEAT
Q3 '25	-$0.09	-$1.20	-1166.77%	MISSED
Q2 '25	-$0.12	-$0.12	-2.13%	MISSED
Q1 '25	-$0.20	-$0.13	34.04%	BEAT

RVPH
Reviva Pharmaceuticals Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest RVPH News

RVPHReviva Pharmaceuticals Holdings Inc.